Skip to main content
logo
L&K Biomed Ltd. (KOSDAQ:156100)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,985.00
-5.00 (-0.13%)
At close: Jul 28, 2026

L&K Biomed Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
39,52738,92036,09229,90519,76715,373
Revenue Growth
10.23%7.84%20.69%51.28%28.59%-20.58%
Gross Profit
32,92532,02230,14225,67814,7927,354
Operating Income
785.51715.123,0782,034-12,738-15,280
Net Income
-7,364-16,2979,743-1,867-13,625-9,669
Earnings Per Share
-353.18-801.67448.00-115.17-1017.14-722.29
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
26,5846,28619,94312,77613,00319,216
Total Debt
27,49719,14823,39713,51325,20122,456
Net Cash (Debt)
-912.93-12,861-3,454-737.76-12,198-3,240
Net Cash Growth
------
Net Cash Per Share
-43.79-632.68-158.80-45.50-910.57-242.05

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-10,843-13,879-7,430-1,370-6,881-10,600
Capital Expenditures
-5,169-2,991-584.84-2,047196.7498.75
Free Cash Flow
-16,012-16,870-8,015-3,417-6,684-10,501
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
83.30%82.28%83.52%85.87%74.83%47.84%
Operating Margin
1.99%1.84%8.53%6.80%-64.44%-99.40%
Pretax Margin
-20.83%-44.05%27.19%-21.63%-82.45%-57.88%
Profit Margin
-18.63%-41.87%27.00%-6.24%-68.93%-62.90%
FCF Margin
-40.51%-43.34%-22.21%-11.43%-33.81%-68.31%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--13.57---
Forward PE
-19.6719.6726.7225.0225.02
PS Ratio
2.257.003.666.795.439.37